CBG Atlas

Safety & reporting
Hub · neutral minor cannabinoids

Minor cannabinoids

What are minor cannabinoids?

The short answer

Minor cannabinoids are the ones cannabis makes in small amounts, which in practice means every cannabinoid bar the two most abundant, THC and CBD. They belong to one chemical family and part ways from there, in structure, in where they come from and in how much anyone knows about them. Their chemical identities are established. The human evidence, for most of them, is thin or missing, and the catalogue is in progress.

At the centre of the group sits cannabigerol. Its acid form, CBGA, is the precursor the plant converts into the others, which is how CBG came to be called the “mother cannabinoid”.

The group, compound by compound, and where the evidence stands on each

Cannabigerol (CBG)

the “mother cannabinoid”: non-intoxicating, and the most studied of the group.

Cannabinol (CBN)

what THC becomes as it ages and oxidises. Widely sold as a sleep aid, though controlled human studies have not established that effect.

Cannabidivarin (CBDV)

CBD’s propyl analog. A completed Phase 2 randomised trial in focal seizures finished level with placebo.

Cannabicyclol (CBL)

what is left when light breaks down CBC (photodegradation); the pharmacology is still being catalogued.

Step one stage back along the plant’s assembly line and you reach the acid precursors, CBGA among them, which have their own hub under the cannabinoid acids. The propyl series gets the same treatment under the varin cannabinoids.

The cannabinoid acids · The varin cannabinoids · How we grade evidence

Before you act on what you have read

Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.

Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.

Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.

Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event →